Curriculum Vitae

C U R R I C U L U M V I T A E

ENMING JOSEPH SU, Ph.D.

Research Assistant Professor

University of Michigan Medical School

Department of Internal Medicine

7301B MSRB III

1150 W. Medical Center Drive

Ann Arbor, MI 48109-0644

enmingsu@umich.edu

734-615-4114

EDUCATION AND TRAINING

Education

9/1986 – 6/1988 Medicine - Shanghai Medical University, China

9/1989 – 5/1991 B. S. in Biology - Oral Roberts University, Tulsa OK

9/1993 – 6/1998 Ph.D. in Pathology – U. of Washington, Seattle WA

ACADEMIC AND INDUSTRIAL APPOINTMENTS

Employment History

6/1998 – 6/2000 Post-Doctoral Fellow, Novartis, Gaithersburg MD

6/2000 – 1/2003 Senior Scientist, Novartis, Gaithersburg MD

2/2003 – 6/2004 Visiting Scientist, American Red Cross, Holland Lab., Rockville MD

6/2004 – 4/2005 Research Associate, University of Maryland, Rockville MD

4/2005 – 8/2009 Research Investigator, University of Michigan, Ann Arbor MI

9/2009 – present Research Assistant Professor, University of Michigan, Ann Arbor, MI

RESEARCH INTERESTS

    • Role of tPA and PDGF-CC in Blood Brain Barrier regulation

    • Effect of Gleevec in acute ischemic stroke therapy and TBI

    • Thrombomodulin/Solulin and their role in APC and thrombolysis

    • Angiogenesis in metabolic syndrome


Recent Awards and Other Professional Activities

1999 Invited Speaker, Vascular Biology 99 Meetings, Washington, DC

2000 Member of American Society of Gene Therapy (ASGT)

2004 Invited Speaker, Xth International Workshop on Molecular & Cellular Biology of Plasminogen Activation, Capri, Italy. 2004

2006 Invited Speaker, Neuroscience Meeting (SFN), Atlanta, GA

2007 Invited Speaker, 18th International Congress on Fibrinolysis and Proteolysis: Proteolysis in the Postgenomic Era

2009 Invited Lecturer, Frontiers in Cardiovascular Science Seminar Series, University of Michigan, Ann Arbor, MI

2010 Invited Lecturer, VINNOVA PROJECT MINI-SYMPOSIUM – 26 August 2010, Karolinska Institutet, Stockholm Sweden

2011 Invited Speaker, XlIIth International Workshop on Molecular & Cellular Biology of Plasminogen Activation, Cambridge, UK

2013 Invited Speaker and Co-Chair, XIVth International Workshop Molecular and Cellular Biology of Plasminogen Activation, University of Notre Dame, South Bend, IN

2015 Invited Speaker, XXVIIth International Symposium on Cerebral Blood Flow, Metabolism and Function, Vancouver, Canada

GRANT SUPPORT

Active

Massey TBI Research Initiative 02/01/2015 – 02/282016

Discovering new treatment options for TBI

Role: PI

1R01 NS079639-01 (PI Lawrence) 07/01/2012 - 06/30/2017

NIH

Mechanism of thrombolytic tPA induced intracerebral hemorrhage after stroke

This proposal will test the hypothesis that during cerebral ischemia tPA plays a duel role, in the blood tPA promotes thromboysis and improves reperfusion, whereas in the abluminal space tPA activates PDGF-CC.

Role: Co-Investigator

R01 HL55374 Lawrence (PI) 07/01/1995 – 3/31/2019

NIH/NHLBI

The Biology of Neuroserpin

The goals of this project are to test the hypothesis that tPA and neuroserpin are expressed in vasoregulatory interneurons, and that in response to neuronal activity tPA and neuroserpin regulate normal neurovascular responses including cerebral blood flow and blood brain barrier (BBB) permeability; and that dysregulation of these neurovascular responses may be a common feature in the development of neurodegenerative disorders.

Role: Co-Investigator

Completed

P01 HL89407 (PI: Lawrence) 04/01/2008 – 03/31/2013

NIH/NHLBI

Novel Targets in Thrombosis and Atherosclerosis

The goals of this project are to explore the relationship between thrombosis/fibrinolysis, inflammation, and lipid metabolism, and test the general hypothesis that previously unrecognized interactions between these three systems can influence the development of cardiovascular diseased.

Role: Co-Investigator

P01 HL54710 (Strickland) 04/01/2007 – 3/30/2012

NIH/NHLBI

Information Signaling Pathways in the Vasculature

The goals of this proposal are to test the hypothesis that during cerebral ischemia tPA, neuroserpin, and LRP function together within the brain to regulate blood-brain-barrier

permeability and neuronal survival. These studies will investigate the mechanisms of this

regulation, and evaluate novel treatments for stroke.

Role: Co-Investigator of Project 2, The Role of tPA and LRP in Ischemic Stroke

1 R43 NS056510-01A2 04/15/2008 – 04/14/2009

NIH/NHLBI $32,553

High Level Expression and Purification of Therapeutic Human and Mouse Neuroserpin

Role: P.I. on Subcontract to University of Michigan from Medigenix, LLC (DRDA 07-4365)

Paion GmbH (Lawrence) 1/1/2008 – 4/30/2008

6 Calendar months $73,729

Solulin in the Treatment of Thrombotic Stroke in Mice: Optimization and Mechanistic Studies

The objective of this study is to provide data on the effects of Solulin and DSPA in a thrombotic model of ischemic stroke.

Role: Co-Investigator

Paion GmbH (Lawrence) 8/1/2006 - 8/31/2007 6 Calendar months $69,577

Efficacy of DSPA and Combined DSPA/Solulin in the Treatment of Thrombotic Stroke in Mice

The objective of this study is to provide data on the effects of Solulin and DSPA in a thrombotic model of ischemic stroke.

Role: Co-Investigator

SEMINARS AND EXTRAMURAL PRESENTATIONS

Recent Awards and Other Professional Activities

1999 Invited Speaker, Vascular Biology 99 Meetings, Washington, DC

2000 Member of American Society of Gene Therapy (ASGT)

2004 Invited Speaker, Xth International Workshop on Molecular & Cellular Biology of Plasminogen Activation, Capri, Italy. 2004

2006 Invited Speaker, Neuroscience Meeting (SFN), Atlanta, GA

2007 Invited Speaker, 18th International Congress on Fibrinolysis and Proteolysis: Proteolysis in the Postgenomic Era

2009 Invited Lecturer, Frontiers in Cardiovascular Science Seminar Series, University of Michigan, Ann Arbor, MI

2010 Invited Lecturer, VINNOVA PROJECT MINI-SYMPOSIUM – 26 August 2010, Karolinska Institutet, Stockholm Sweden

2011 Invited Speaker, XlIIth International Workshop on Molecular & Cellular Biology of Plasminogen Activation, Cambridge, UK

2013 Invited Speaker and Co-Chair, XIVth International Workshop Molecular and Cellular Biology of Plasminogen Activation, University of Notre Dame, South Bend, IN

2015 Invited Speaker, XXVIIth International Symposium on Cerebral Blood Flow, Metabolism and Function, Vancouver, Canada

PATENTS/APPLICATIONS

    1. Liau G, Stefansson S, Su J. World patent application filed for delivery of sphingosine kinase as a therapeutic agent to induce blood vessel formation for the treatment of ischemic diseases U.S Patent Number 6,610,534 B2; Aug. 26, 2003.

    2. Liau G, Stefansson S, Su J. Identification of short peptide sequences that specifically bind to endothelial cells. Publication No. US 2006/0223756 A1.

    3. Lawrence DA, Cale J, Su EJ, Strickland D. Plasminogen activator inhibitor-1 may alter lipid metabolism by a previously unidentified mechanism. 2007.

    4. Erikksson, K-U, Lawrence, DA, Su, EJ, Strickland D, Yeppes M, Fredriksson L; Methods and Compositions for Modulation of Blood-Neural Barrier. U.S. Patent Number 11/736,499; PCT/US2007066804; 03.12.2008.

Patent Applications

    1. Lawrence, DA, Cale J, Su, EJ, Strickland, D. Cory Emal, Mark Warnock.

Plasminogen activator inhibitor-1 Inhibitors and methods of use thereof to modulate lipid metabolism. 2007.

BIBLIOGRAPHY

Peer-Reviewed Publications

    1. Luo W, Su EJ, Wang J, Wang H, Guo C, Pawar A, Campbell AD, Lawrence DA, Eitzman DT. Increased stroke size following MCA occlusion in a mouse model of sickle cell disease. Blood. 2014 Mar 20;123(12):1965-7.

    2. Sashindranath M, Sales E, Daglas M, Freeman R, Samson AL, Cops EJ, Beckham S, Galle A, McLean C, Morganti-Kossmann C, Rosenfeld JV, Madani R, Vassalli JD, Su EJ, Lawrence DA, Medcalf RL. The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain. 2012 Jul 20. PMID: 22822039

    3. Frieler RA, Ray JJ, Meng H, Ramnarayanan SP, Usher MG, Su EJ, Berger S, Pinsky DJ, Lawrence DA, Wang MM, Mortensen RM. Myeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex. J Am Heart Assoc. 2012 Oct;1(5):e002584. doi: 10.1161/JAHA.112.002584. Epub 2012 Oct 25. PMCID: PMC3541615

    4. Fredriksson L, Nilsson I, Su EJ, Andrae J, Ding H, Betsholtz C, Eriksson U, Lawrence DA. Platelet-Derived Growth Factor C Deficiency in C57BL/6 Mice Leads to Abnormal Cerebral Vascularization, Loss of Neuroependymal Integrity, and Ventricular Abnormalities. Am J Pathol. 2012 Jan 6. PMID: 22230248

    5. Su EJ, Geyer M, Wahl M, Mann K, Ginsburg D, Brohmann H, Petersen KU, Lawrence DA. The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model.J Thromb Haemost. 2011 Jun;9(6):1174-82. PMCID: PMC3111949

    6. Su EJ, Fredriksson L, Schielke GP, Eriksson U, Lawrence DA. Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J Thromb Haemost, 2009 Jul; 7 Suppl 1:155-8. PMCID: PMC291222

    7. Hyman MC, Petrovic-Djergovic D, Visovatti SH, Liao H, Yanamadala S, Bouïs D, Su EJ, Lawrence DA, Broekman MJ, Marcus AJ, Pinsky DJ. Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest. 2009;119(5):1136-49. PMCID: PMC2673847

    8. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain integrity during ischemic stroke. Nat. Med. 2008;14:731-737. (see commentaries Nat. Med, 2008; 14: 712-713; Science Signaling (Editors' Choice) 2008; 1(28), ec255 Ed (doi:0.1126/scisignal.128ec255); Nature Reviews Drug Discovery, 2008; 7, 643 (doi:10.1038/nrd2642); SciBX: Science–Business eXchange, 2008; 1(23): 1-4.) PMCID: PMC2811427

    9. Stefansson S, Su EJ, Ishigami S, Cale JM, Gao Y, Gorlatova N, Lawrence DA. The contributions of integrin affinity and intergri-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J Bio Chem, 2007; 282:15679-15689.

    10. Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence D.A. Effect of Pharmacologic PAI-1 Inhibition on Cell Motility and Tumor Angiogenesis. J Thromb Haemost. 4:2710-2715, 2006.

    11. Cao C, Lawrence DA, Li Y, Von ArnimCA, Herz J, Su EJ, Makarova A, Hyman BT, Strickland DK, Zhang L; Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J. 2006 May 3;25(9):1860-70.

    12. Su EJ, Cioffi CL,Stefansson S, Mittereder N,Garay M, Hreniuk D, Liau G. Gene Therapy Vector-mediated Expression of Insulin-like Growth Factors Protects Cardiomyocytes from Apoptosis and Enhances Neovascularization. Am J Physiol Heart Circ Physiol 2003 Apr 284(4):H1429-40.

    13. Ancellin N, Colmont C, Su J, Li Q, Mittereder N, Chae SS, Stefansson S, Liau G, Hla T. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002 Feb 22; 277(8):6667-75.

    14. Liau G, Su EJ, Dixon KD. Clinical efforts to modulate angiogenesis in the adult: gene therapy versus conventional approaches. Drug Discov Today 2001 Jul 1; 6(13): 689-697.

    15. Su EJ, Stevenson SC, Rollence M, Marshall-Neff J, Liau G: A genetically modified adenoviral vector exhibits enhanced gene transfer of human smooth muscle cells. J Vasc Res 2001 Sep-Oct; 38(5): 471-8.

    16. Su EJ, Lombardi DM, Wiener J, Daemen MJAP, Reidy MA, Schwartz SM: Mitogenic effect of angiotensin II on rat carotid arteries and type II or III mesenteric microvessels, but not type I mesenteric microvessels, is mediated by endogenous basic fibroblast growth factor. Circ Res. 1998; 82:321-327.

    17. Su EJ, Lombardi DM, Siegal J, Schwartz SM: Angiotensin II indues smooth muscle replication in the vessel wall independent of blood pressure. Hypertension. 1998; 31(6): 1331-7.

    18. deBlois D, Lombardi DM, Su EJ, Clowes AW, Schwartz SM, Giachelli CM: Angiotensin II induction of osteopontin expression and DNA replication in rat arteries. Hypertension. 1996; 28:1055-1063.

    19. deBlois D, Schwartz SM, Van Kleef EM, Su EJ, Griffin KA, Bidani AK, Daemen MJAP, Lombardi DM: Chronic alpha1-adrenoreceptor stimulation increases DNA synthesis in rat arterial wall:modulation of responsiveness after vascular injury. Arteriosclerosis, Thrombosis, and Vascular Biology 1996; 16:1122-1129.

Non Peer-Reviewed Publications

1.Su EJ, Fredriksson L, Schielke GP, Eriksson U, Lawrence DA. Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke.J Thromb Haemost. 2009 Jul; 7 Suppl 1:155-8. PMID: 19630790

2. Su EJ, Lawrence DA. α2 Antiplasmin and microvascular thrombosis in ischemic stroke. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2522-3.

BOOK CHAPTERS, INVITED REVIEWS, AND COMMENTARIES

1. Lawrence DA, Su EJ. The functional dissonance of platelets. Blood. 120:1154-1155 2012.

2. Lawrence DA, Su EJ, Arbor A, Petersen KU. Thrombomodulin and the brain: past, present, and future. Neurology. 2012 Apr 17;78(16):1280-1. PMID: 22508851